This is the authors' abstract. We don't add key points for this paper.
β Adrenergic receptors, in particular β2 subtype, are key regulators of glucose homeostasis. Previous studies showed that activation of hepatic and adipose tissue β adrenergic receptors mediates insulin desensitizing effects. On the contrary, activation of β adrenergic receptors in the skeletal muscle enhances glucose uptake. However, there is a lot of controversy regarding the metabolic effects of systemic administration of either β adrenergic receptor agonists or antagonists. β2 Agonists have been shown to substantially impair glucose homeostasis while improving it with long-term systemic administration. In the same context, acute and chronic systemic use of certain types of β blockers have been found to enhance insulin action. In this review article, we try to elaborate the underlying mechanisms that regulate glucose metabolism after acute and chronic systemic use of β adrenergic receptor agonists and antagonists in an attempt to answer the question "Do β adrenergic receptors induce or protect against insulin resistance?"
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ibrahim et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: